Literature DB >> 31526757

Recruit or Reboot? How Does Anti-PD-1 Therapy Change Tumor-Infiltrating Lymphocytes?

Margaret K Callahan1, Jedd D Wolchok2.   

Abstract

It has been widely assumed that PD-1 blockade works by reinvigorating ("rebooting") pre-existing exhausted tumor-infiltrating ilymphocytes (TILs). A recent study challenges this paradigm, demonstrating that the majority of tumor-specific TILs after anti-PD-1 treatment have TCRs not identified in the tumor pre-therapy, suggesting they are newly recruited post-therapy.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31526757     DOI： 10.1016/j.ccell.2019.08.009

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  8 in total

1.  Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer.

Authors:  Rami S Vanguri; Jia Luo; Andrew T Aukerman; Jacklynn V Egger; Christopher J Fong; Natally Horvat; Andrew Pagano; Jose de Arimateia Batista Araujo-Filho; Luke Geneslaw; Hira Rizvi; Ramon Sosa; Kevin M Boehm; Soo-Ryum Yang; Francis M Bodd; Katia Ventura; Travis J Hollmann; Michelle S Ginsberg; Jianjiong Gao; Matthew D Hellmann; Jennifer L Sauter; Sohrab P Shah
Journal:  Nat Cancer       Date:  2022-08-29

Review 2.  Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications.

Authors:  Feifei Teng; Min Li; Jinming Yu
Journal:  BMC Med       Date:  2020-09-18       Impact factor: 8.775

3.  A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma.

Authors:  Weinan Guo; Jinyuan Ma; Sen Guo; Huina Wang; Sijia Wang; Qiong Shi; Lin Liu; Tao Zhao; Fengfan Yang; Shuyang Chen; Jianru Chen; Jianhong Zhao; Chen Yu; Xiuli Yi; Yuqi Yang; Jingjing Ma; Qingrong Ni; Guannan Zhu; Tianwen Gao; Chunying Li
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751

Review 4.  Applications of Single-Cell Omics to Dissect Tumor Microenvironment.

Authors:  Tingting Guo; Weimin Li; Xuyu Cai
Journal:  Front Genet       Date:  2020-11-27       Impact factor: 4.599

5.  Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma.

Authors:  Jeppe Sejerø Holm; Samuel A Funt; Dean F Bajorin; Sine Reker Hadrup; Annie Borch; Kamilla Kjærgaard Munk; Anne-Mette Bjerregaard; James L Reading; Colleen Maher; Ashley Regazzi; Phillip Wong; Hikmat Al-Ahmadie; Gopa Iyer; Tripti Tamhane; Amalie Kai Bentzen; Nana Overgaard Herschend; Susan De Wolf; Alexandra Snyder; Taha Merghoub; Jedd D Wolchok; Morten Nielsen; Jonathan E Rosenberg
Journal:  Nat Commun       Date:  2022-04-11       Impact factor: 17.694

6.  Consistent expression of PD-L1 in tumor microenvironment with peripheral PD-1/PD-L1 in circulating T lymphocytes of operable breast cancer: a diagnostic test.

Authors:  Keyu Yuan; Jiangping Wu; Yanjie Zhao; Shuzhen Lyu; Quan Zhou; Feng Shi; Yanping Li; Qingkun Song
Journal:  Diagn Pathol       Date:  2022-09-10       Impact factor: 3.196

7.  Poor prognosis, hypomethylation, and immune infiltrates are associated with downregulation of INMT in head and neck squamous cell carcinoma.

Authors:  Kun Cui; Xi Yao; Zhengbo Wei; Yujia Yang; Xinli Liu; Zhongheng Huang; Huimin Huo; Jinping Tang; Ying Xie
Journal:  Front Genet       Date:  2022-09-15       Impact factor: 4.772

8.  The Prognostic Impact of Combined Tumor-Infiltrating Lymphocytes and Pretreatment Blood Lymphocyte Percentage in Locally Advanced Nasopharyngeal Carcinoma.

Authors:  Zhuochen Cai; Jiali Jiang; Laiji Huang; Yawei Yuan; Ronghui Zheng; Jiangyu Zhang; Wenze Qiu
Journal:  Front Oncol       Date:  2022-01-18       Impact factor: 6.244
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.